U.S. Markets open in 8 hrs 20 mins
  • Gold

    1,790.10
    -3.30 (-0.18%)
     
  • EUR/USD

    1.1608
    +0.0005 (+0.0464%)
     
  • 10-Yr Bond

    1.6190
    0.0000 (0.00%)
     
  • Vix

    15.98
    +0.74 (+4.86%)
     
  • GBP/USD

    1.3774
    +0.0010 (+0.0744%)
     
  • USD/JPY

    114.0230
    -0.1060 (-0.0929%)
     
  • BTC-USD

    61,306.00
    -1,290.58 (-2.06%)
     
  • CMC Crypto 200

    1,492.22
    -12.93 (-0.86%)
     
  • FTSE 100

    7,277.62
    +54.80 (+0.76%)
     
  • Nikkei 225

    28,985.38
    -120.62 (-0.41%)
     

DarioHealth: Q2 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of DarioHealth (NASDAQ:DRIO) moved higher by 2% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 423.08% year over year to ($0.68), which beat the estimate of ($1.40).

Revenue of $1,787,000 up by 8.24% from the same period last year, which beat the estimate of $1,550,000.

Outlook

DarioHealth hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Aug 12, 2020

View more earnings on DRIO

Time: 09:00 AM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2224/36466

Technicals

52-week high: $18.84

52-week low: $0.20

Price action over last quarter: Up 123.19%

Company Profile

DarioHealth Corp is a digital health company. It is engaged in the development and commercialization of patented and proprietary technology that provides consumers with laboratory-testing capabilities using smartphones and other mobile devices. The company's product, Dario Blood sugar monitor is a mobile, real-time, cloud-based, diabetes management solution based on a multi-featured software application combined with a blood glucose monitoring device. The group operates internationally and derives revenues from the sale of its Dario smart meter and related device-specific disposables test strip cartridges and lancets. The company generates the majority of the revenue by sales of its product.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.